Quick Answer
Zymeworks Inc. reported Research And Development Expense of $143.62 million for the year ending 2023.
- Zymeworks Inc. showed a decrease of -31.1% in Research And Development Expense from 2022 to 2023.
- This data is from Zymeworks Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2024.
- XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $49.89 million | Q1 2022: $62.51 million | Q2 2022: $56.02 million | Q3 2022: $37.10 million | Q1 2023: $45.91 million | Q2 2023: $39.41 million | Q3 2023: $32.78 million | Q1 2024: $32.04 million.
- Over the full 4 years of available data (2020 to 2023), Zymeworks Inc.'s Research And Development Expense has declined by 16.1%.
- Historical annual values: Fiscal year 2023: $143.62 million | Fiscal year 2022: $208.60 million | Fiscal year 2021: $199.75 million | Fiscal year 2020: $171.20 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: